{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T09:03:23Z","timestamp":1772269403449,"version":"3.50.1"},"reference-count":43,"publisher":"PeerJ","license":[{"start":{"date-parts":[[2017,4,27]],"date-time":"2017-04-27T00:00:00Z","timestamp":1493251200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004442","name":"National Science Centre","doi-asserted-by":"crossref","award":["Opus2, 2011\/03\/B\/NZ7\/05949"],"award-info":[{"award-number":["Opus2, 2011\/03\/B\/NZ7\/05949"]}],"id":[{"id":"10.13039\/501100004442","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Huntington\u2019s disease (HD) is a rare familial autosomal dominant neurodegenerative disorder characterized by progressive degeneration of medium spiny neurons (MSNs) located in the striatum. Currently available treatments of HD are only limited to alleviating symptoms; therefore, high expectations for an effective therapy are associated with potential replacement of lost neurons through stimulation of postnatal neurogenesis. One of the drugs of potential interest for the treatment of HD is riluzole, which may act as a positive modulator of adult neurogenesis, promoting replacement of damaged MSNs. The aim of this study was to evaluate the effects of chronic riluzole treatment on a novel HD-like transgenic mouse model, based on the genetic ablation of the transcription factor TIF-IA. This model is characterized by selective and progressive degeneration of MSNs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Selective ablation of TIF-IA in MSNs (TIF-IA\n                      <jats:sup>D1RCre<\/jats:sup>\n                      mice) was achieved by Cre-based recombination driven by the dopamine 1 receptor (D1R) promoter in the C57Bl\/6N mouse strain. Riluzole was administered for 14 consecutive days (5\u00a0mg\/kg, i.p.; 1\u00d7\u00a0daily) starting at six weeks of age. Behavioral analysis included a motor coordination test performed on 13-week-old animals on an accelerated rotarod (4\u201340 r.p.m.; 5 min). To visualize the potential effects of riluzole treatment, the striata of the animals were stained by immunohistochemistry (IHC) and\/or immunofluorescence (IF) with Ki67 (marker of proliferating cells), neuronal markers (NeuN, MAP2, DCX), and markers associated with neurodegeneration (GFAP, 8OHdG, FluoroJade C). Additionally, the morphology of dendritic spines of neurons was assessed by a commercially available FD Rapid Golgi Stain\u2122 Kit.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A comparative analysis of IHC staining patterns with chosen markers for the neurodegeneration process in MSNs did not show an effect of riluzole on delaying the progression of MSN cell death despite an observed enhancement of cell proliferation as visualized by the Ki67 marker. A lack of a riluzole effect was also reflected by the behavioral phenotype associated with MSN degeneration. Moreover, the analysis of dendritic spine morphology did not show differences between mutant and control animals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>\n                      Despite the observed increase in newborn cells in the subventricular zone (SVZ) after riluzole administration, our study did not show any differences between riluzole-treated and non-treated mutants, revealing a similar extent of the neurodegenerative phenotype evaluated in 13-week-old TIF-IA\n                      <jats:sup>D1RCre<\/jats:sup>\n                      animals. This could be due to either the treatment paradigm (relatively low dose of riluzole used for this study) or the possibility that the effects were simply too weak to have any functional meaning. Nevertheless, this study is in line with others that question the effectiveness of riluzole in animal models and raise concerns about the utility of this drug due to its rather modest clinical efficacy.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.7717\/peerj.3240","type":"journal-article","created":{"date-parts":[[2017,4,27]],"date-time":"2017-04-27T03:59:21Z","timestamp":1493265561000},"page":"e3240","source":"Crossref","is-referenced-by-count":1,"title":["Lack of riluzole efficacy in the progression of the neurodegenerative phenotype in a new conditional mouse model of striatal degeneration"],"prefix":"10.7717","volume":"5","author":[{"given":"Grzegorz","family":"Kreiner","sequence":"first","affiliation":[{"name":"Institute of Pharmacology, Polish Academy of Sciences, Dept. Brain Biochemistry, Krak\u00f3w, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Rafa-Zab\u0142ocka","sequence":"additional","affiliation":[{"name":"Institute of Pharmacology, Polish Academy of Sciences, Dept. Brain Biochemistry, Krak\u00f3w, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piotr","family":"Chmielarz","sequence":"additional","affiliation":[{"name":"Institute of Pharmacology, Polish Academy of Sciences, Dept. Brain Biochemistry, Krak\u00f3w, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Bagi\u0144ska","sequence":"additional","affiliation":[{"name":"Institute of Pharmacology, Polish Academy of Sciences, Dept. Brain Biochemistry, Krak\u00f3w, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irena","family":"Nalepa","sequence":"additional","affiliation":[{"name":"Institute of Pharmacology, Polish Academy of Sciences, Dept. Brain Biochemistry, Krak\u00f3w, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4443","published-online":{"date-parts":[[2017,4,27]]},"reference":[{"key":"10.7717\/peerj.3240\/ref-1","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2174\/187152708784083858","article-title":"The role of neurogenesis in neurodegenerative diseases and its implications for therapeutic development","volume":"7","author":"Abdipranoto","year":"2008","journal-title":"CNS & Neurological Disorders\u2014Drug Targets"},{"key":"10.7717\/peerj.3240\/ref-2","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.expneurol.2004.02.003","article-title":"Co-treatment with riluzole and GDNF is necessary for functional recovery after ventral root avulsion injury","volume":"187","author":"Bergerot","year":"2004","journal-title":"Experimental Neurology"},{"key":"10.7717\/peerj.3240\/ref-3","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1111\/j.1530-0277.2009.00976.x","article-title":"Preclinical evaluation of riluzole: assessments of ethanol self-administration and ethanol withdrawal symptoms","volume":"33","author":"Besheer","year":"2009","journal-title":"Alcoholism, Clinical and Experimental Research"},{"key":"10.7717\/peerj.3240\/ref-4","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.pneurobio.2006.11.002","article-title":"Radial glial origin of the adult neural stem cells in the subventricular zone","volume":"83","author":"Bonfanti","year":"2007","journal-title":"Progress in Neurobiology"},{"key":"10.7717\/peerj.3240\/ref-5","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/1471-2202-13-38","article-title":"Riluzole neuroprotection in a Parkinson\u2019s disease model involves suppression of reactive astrocytosis but not GLT-1 regulation","volume":"13","author":"Carbone","year":"2012","journal-title":"BMC Neuroscience"},{"key":"10.7717\/peerj.3240\/ref-6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.pbb.2015.08.001","article-title":"Disruption of glucocorticoid receptors in the noradrenergic system leads to BDNF up-regulation and altered serotonergic transmission associated with a depressive-like phenotype in female GR(DBHCre) mice","volume":"137","author":"Chmielarz","year":"2015","journal-title":"Pharmacology, Biochemistry and Behavior"},{"issue":"8","key":"10.7717\/peerj.3240\/ref-7","doi-asserted-by":"publisher","first-page":"e72632","DOI":"10.1371\/journal.pone.0072632","article-title":"Inactivation of glucocorticoid receptor in noradrenergic system influences anxiety- and depressive-like behavior in mice","volume":"8","author":"Chmielarz","year":"2013","journal-title":"PLOS ONE"},{"key":"10.7717\/peerj.3240\/ref-8","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s00429-010-0245-1","article-title":"Changes in dendritic complexity and spine morphology in transgenic mice expressing human wild-type tau","volume":"214","author":"Dickstein","year":"2010","journal-title":"Brain Structure and Function"},{"key":"10.7717\/peerj.3240\/ref-9","doi-asserted-by":"publisher","first-page":"S233","DOI":"10.1212\/WNL.47.6_Suppl_4.233S","article-title":"The pharmacology and mechanism of action of riluzole","volume":"47","author":"Doble","year":"1996","journal-title":"Neurology"},{"key":"10.7717\/peerj.3240\/ref-10","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.pneurobio.2005.04.002","article-title":"Adult neurogenesis and repair of the adult CNS with neural progenitors, precursors, and stem cells","volume":"75","author":"Emsley","year":"2005","journal-title":"Progress in Neurobiology"},{"key":"10.7717\/peerj.3240\/ref-11","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s13311-013-0244-z","article-title":"Treatment of Huntington\u2019s disease","volume":"11","author":"Frank","year":"2014","journal-title":"Neurotherapeutics"},{"key":"10.7717\/peerj.3240\/ref-12","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.expneurol.2005.11.010","article-title":"Riluzole, unlike the AMPA antagonist RPR119990, reduces motor impairment and partially prevents motoneuron death in the wobbler mouse, a model of neurodegenerative disease","volume":"198","author":"Fumagalli","year":"2006","journal-title":"Experimental Neurology"},{"key":"10.7717\/peerj.3240\/ref-13","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.cell.2004.06.018","article-title":"Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules","volume":"118","author":"Gauthier","year":"2004","journal-title":"Cell"},{"key":"10.7717\/peerj.3240\/ref-14","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2165\/00019053-200220060-00002","article-title":"Cost effectiveness of treatments for amyotrophic lateral sclerosis: a review of the literature","volume":"20","author":"Ginsberg","year":"2002","journal-title":"Pharmacoeconomics"},{"key":"10.7717\/peerj.3240\/ref-15","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1517\/14728222.9.4.639","article-title":"Novel therapeutic targets for Huntington\u2019s disease","volume":"9","author":"Hannan","year":"2005","journal-title":"Expert Opinion on Therapeutic Targets"},{"key":"10.7717\/peerj.3240\/ref-16","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.nbd.2005.07.007","article-title":"Evaluation of the benzothiazole aggregation inhibitors riluzole and PGL-135 as therapeutics for Huntington\u2019s disease","volume":"21","author":"Hockly","year":"2006","journal-title":"Neurobiology of Disease"},{"key":"10.7717\/peerj.3240\/ref-17","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1096\/fj.02-0143fje","article-title":"Riluzole enhances expression of brain-derived neurotrophic factor with consequent proliferation of granule precursor cells in the rat hippocampus","volume":"16","author":"Katoh-Semba","year":"2002","journal-title":"FASEB Journal"},{"key":"10.7717\/peerj.3240\/ref-18","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.pneurobio.2007.02.005","article-title":"Drug targeting of dysregulated transcription in Huntington\u2019s disease","volume":"83","author":"Kazantsev","year":"2007","journal-title":"Progress in Neurobiology"},{"key":"10.7717\/peerj.3240\/ref-19","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S0165-0270(02)00007-9","article-title":"The utility of Ki-67 and BrdU as proliferative markers of adult neurogenesis","volume":"115","author":"Kee","year":"2002","journal-title":"Journal of Neuroscience Methods"},{"key":"10.7717\/peerj.3240\/ref-20","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.neulet.2009.03.016","article-title":"Effectiveness of riluzole in suppressing spasticity in the spinal cord injured rat","volume":"455","author":"Kitzman","year":"2009","journal-title":"Neuroscience Letters"},{"key":"10.7717\/peerj.3240\/ref-21","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3389\/fncel.2015.00056","article-title":"Compensatory mechanisms in genetic models of neurodegeneration: are the mice better than humans?","volume":"9","author":"Kreiner","year":"2015","journal-title":"Frontiers in Cellular Neuroscience"},{"key":"10.7717\/peerj.3240\/ref-22","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1038\/cdd.2013.66","article-title":"A neuroprotective phase precedes striatal degeneration upon nucleolar stress","volume":"20","author":"Kreiner","year":"2013","journal-title":"Cell Death and Differentiation"},{"key":"10.7717\/peerj.3240\/ref-23","doi-asserted-by":"publisher","first-page":"717","DOI":"10.3762\/bjoc.9.82","article-title":"Recent progress in the discovery of small molecules for the treatment of amyotrophic lateral sclerosis (ALS)","volume":"9","author":"Limpert","year":"2013","journal-title":"Beilstein Journal of Organic Chemistry"},{"key":"10.7717\/peerj.3240\/ref-24","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1172\/JCI40543","article-title":"Stem cells in human neurodegenerative disorders\u2013time for clinical translation?","volume":"120","author":"Lindvall","year":"2010","journal-title":"Journal of Clinical Investigation"},{"issue":"9","key":"10.7717\/peerj.3240\/ref-25","doi-asserted-by":"publisher","first-page":"e25088","DOI":"10.1371\/journal.pone.0025088","article-title":"New striatal neurons in a mouse model of progressive striatal degeneration are generated in both the subventricular zone and the striatal parenchyma","volume":"6","author":"Luzzati","year":"2011","journal-title":"PLOS ONE"},{"issue":"3","key":"10.7717\/peerj.3240\/ref-26","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001447.pub3","article-title":"Riluzole for amyotrophic lateral sclerosis (ALS)\/motor neuron disease (MND)","volume":"14","author":"Miller","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.7717\/peerj.3240\/ref-27","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1242\/dev.116657","article-title":"Striatal astrocytes produce neuroblasts in an excitotoxic model of Huntington\u2019s disease","volume":"142","author":"Nato","year":"2015","journal-title":"Development"},{"key":"10.7717\/peerj.3240\/ref-28","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1097\/JGP.0b013e318196a632","article-title":"Modeling brain reserve: experience-dependent neuronal plasticity in healthy and Huntington\u2019s disease transgenic mice","volume":"17","author":"Nithianantharajah","year":"2009","journal-title":"American Journal of Geriatric Psychiatry"},{"key":"10.7717\/peerj.3240\/ref-29","doi-asserted-by":"publisher","first-page":"12759","DOI":"10.1523\/JNEUROSCI.2439-08.2008","article-title":"Activation of an endogenous suicide response after perturbation of rRNA synthesis leads to neurodegeneration in mice","volume":"28","author":"Parlato","year":"2008","journal-title":"Journal of Neuroscience"},{"key":"10.7717\/peerj.3240\/ref-30","doi-asserted-by":"publisher","first-page":"S642","DOI":"10.1016\/S0924-977X(14)71033-8","article-title":"Involvement of noradrenergic system in Parkinson\u2019s disease\u2014study on novel transgenic mouse models","volume":"24","author":"Rafa-Zab\u0142ocka","year":"2014","journal-title":"European Neuropsychopharmacology"},{"key":"10.7717\/peerj.3240\/ref-31","doi-asserted-by":"publisher","first-page":"874387","DOI":"10.1155\/2012\/874387","article-title":"Hippocampal neurogenesis, cognitive deficits and affective disorder in Huntington\u2019s disease","volume":"2012","author":"Ransome","year":"2012","journal-title":"Neural Plasticity"},{"key":"10.7717\/peerj.3240\/ref-32","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1523\/JNEUROSCI.0590-10.2011","article-title":"Nucleolar disruption in dopaminergic neurons leads to oxidative damage and parkinsonism through repression of mammalian target of rapamycin signaling","volume":"31","author":"Rieker","year":"2011","journal-title":"Journal of Neuroscience"},{"key":"10.7717\/peerj.3240\/ref-33","doi-asserted-by":"publisher","first-page":"340","DOI":"10.5414\/NP300638","article-title":"Clinical neuropathology practice guide 5-2013: markers of neuronal maturation","volume":"32","author":"Sarnat","year":"2013","journal-title":"Clinical Neuropathology"},{"key":"10.7717\/peerj.3240\/ref-34","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/jnc.13606","article-title":"In vivo assessment of riluzole as a potential therapeutic drug for spinocerebellar ataxia type 3","volume":"138","author":"Schmidt","year":"2016","journal-title":"Journal of Neurochemistry"},{"key":"10.7717\/peerj.3240\/ref-35","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.brainres.2004.11.054","article-title":"Fluoro-Jade C results in ultra high resolution and contrast labeling of degenerating neurons","volume":"1035","author":"Schmued","year":"2005","journal-title":"Brain Research"},{"key":"10.7717\/peerj.3240\/ref-36","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S0014-2999(99)00503-8","article-title":"Riluzole decreases the abstinence syndrome and physical dependence in morphine-dependent mice","volume":"379","author":"Sepulveda","year":"1999","journal-title":"European Journal of Pharmacology"},{"key":"10.7717\/peerj.3240\/ref-37","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.expneurol.2011.11.044","article-title":"Comparative effects of glibenclamide and riluzole in a rat model of severe cervical spinal cord injury","volume":"233","author":"Simard","year":"2012","journal-title":"Experimental Neurology"},{"key":"10.7717\/peerj.3240\/ref-38","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1111\/j.0953-816X.2004.03374.x","article-title":"Dendritic spine pathology and deficits in experience-dependent dendritic plasticity in R6\/1 Huntington\u2019s disease transgenic mice","volume":"19","author":"Spires","year":"2004","journal-title":"European Journal of Neuroscience"},{"key":"10.7717\/peerj.3240\/ref-39","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00259-007-0615-y","article-title":"Neuroprotective effects of riluzole in Huntington\u2019s disease","volume":"35","author":"Squitieri","year":"2008","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"key":"10.7717\/peerj.3240\/ref-40","doi-asserted-by":"publisher","first-page":"878","DOI":"10.3390\/molecules15020878","article-title":"3-Nitropropionic acid as a tool to study the mechanisms involved in Huntington\u2019s disease: past, present and future","volume":"15","author":"Tunez","year":"2010","journal-title":"Molecules"},{"key":"10.7717\/peerj.3240\/ref-41","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1016\/j.neuropharm.2011.11.016","article-title":"Neuroprotective effects of riluzole in early phase Parkinson\u2019s disease on clinically relevant parameters in the marmoset MPTP model","volume":"62","author":"Verhave","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.7717\/peerj.3240\/ref-42","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/npp.2008.191","article-title":"Novelty determines the effects of olfactory enrichment on memory and neurogenesis through noradrenergic mechanisms","volume":"34","author":"Veyrac","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"10.7717\/peerj.3240\/ref-43","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.molcel.2005.05.023","article-title":"Genetic inactivation of the transcription factor TIF-IA leads to nucleolar disruption, cell cycle arrest, and p53-mediated apoptosis","volume":"19","author":"Yuan","year":"2005","journal-title":"Molecular Cell"}],"container-title":["PeerJ"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/peerj.com\/articles\/3240.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/3240.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/3240.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/3240.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T17:01:38Z","timestamp":1589734898000},"score":1,"resource":{"primary":{"URL":"https:\/\/peerj.com\/articles\/3240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,27]]},"references-count":43,"alternative-id":["10.7717\/peerj.3240"],"URL":"https:\/\/doi.org\/10.7717\/peerj.3240","archive":["CLOCKSS","LOCKSS","Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.7287\/peerj.3240v0.2\/reviews\/2","asserted-by":"object"},{"id-type":"doi","id":"10.7287\/peerj.3240v0.1\/reviews\/1","asserted-by":"object"},{"id-type":"doi","id":"10.7287\/peerj.3240v0.1\/reviews\/2","asserted-by":"object"}]},"ISSN":["2167-8359"],"issn-type":[{"value":"2167-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,27]]},"article-number":"e3240"}}